GSK, RSV and Shingles
GSK pursues co-administration of RSV and shingles vaccines
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new hope.
GSK's experimental herpes vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK Advances mRNA Flu Vaccine to Phase III Trials After Positive Results
GSK PLC, a major player in the,Healthcare sector,, has reported positive initial results from its seasonal flu vaccine using mRNA technology. The FTSE 100 company announced that the phase II trial of its mRNA-based influenza vaccine has shown promising im...
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
Yahoo Finance9h
Down another 6% in a week! So will the GSK share price ever recover?
To fund GSK’s R&D efforts she froze the dividend at 80p per share for yonks. In 2022, it was slashed to 44p then to 42p the ...
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
MyChesCo on MSN5d
Healthcare Services Group, Inc. Strengthens Leadership with Key Financial Appointments
BENSALEM, PA — Healthcare Services Group, Inc. (NASDAQ: HCSG) has announced significant leadership changes, appointing Vikas ...
FiercePharma10d
Pfizer, Sanofi, GSK among the winners of the 2024 Fierce Pharma Marketing Awards
Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
USA Today4d
Best health care stocks July 2024
Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...